C4 Therapeutics, Inc. reported earnings results for the second quarter ended June 30, 2022. For the second quarter, the company reported net loss was USD 27.41 million compared to USD 22.58 million a year ago. Basic loss per share from continuing operations was USD 0.56 compared to USD 0.51 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.84 USD | -3.01% | -11.68% | -14.34% |
May. 09 | Stifel Adjusts Price Target on C4 Therapeutics to $14 From $13, Maintains Buy Rating | MT |
May. 08 | C4 Therapeutics Shares Decline as Q1 Revenue Misses Estimates | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.34% | 333M | |
+48.64% | 56.65B | |
-6.44% | 39.44B | |
+40.60% | 39.03B | |
-11.17% | 26.86B | |
+14.28% | 26.75B | |
-21.40% | 19.03B | |
+0.96% | 12.28B | |
+25.64% | 12.26B | |
+27.04% | 12.04B |
- Stock Market
- Equities
- CCCC Stock
- News C4 Therapeutics, Inc.
- C4 Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2022